Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNTO 95 with or without dacarbazine versus dacarbazine in stage IV melanoma
2004-002130-18Phase 2Completed
- Sponsor
- Janssen Biotech
- Start
- May 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of intetumumab in melanoma (3 arms), sponsored by Janssen Biotech. Primary endpoint: Progression-free survival. Started May 2006; status: completed.
02
Drugs
intetumumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2004-002130-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002130-18.